Jun 30, 2025
Shionogi files in Japan to expand pediatric use of COVID-19 antiviral
Japanese drugmaker Shionogi has filed a supplemental application in Japan to broaden the use of its oral antiviral Xocova (ensitrelvir), aiming to include children as young as six who weigh at least 20 kilograms.
Read More
Jun 30, 2025
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Treatment of COVID-19 in Pediatric Patients Aged 6 Years and Older
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Treatment of COVID-19 in Pediatric Patients Aged 6 Years and Older.
Read More
Jun 28, 2025
The Ministry of Health clarified the recommendations for the treatment of coronavirus
The Ministry of Health recommends starting antiviral therapy as early as possible, no later than 7-8 days from the onset of symptoms, which refers to etiotropic treatment (aimed at eliminating the cause of the disease - ed.).
Read More